GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » Net Margin %

Neos Therapeutics (Neos Therapeutics) Net Margin % : -39.18% (As of Sep. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Neos Therapeutics's Net Income for the three months ended in Sep. 2020 was $-4.91 Mil. Neos Therapeutics's Revenue for the three months ended in Sep. 2020 was $12.54 Mil. Therefore, Neos Therapeutics's net margin for the quarter that ended in Sep. 2020 was -39.18%.

The historical rank and industry rank for Neos Therapeutics's Net Margin % or its related term are showing as below:

NEOS' s Net Margin % Range Over the Past 10 Years
Min: -2750.53   Med: -811.74   Max: -26.14
Current: -38.35


NEOS's Net Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.25 vs NEOS: -38.35

Neos Therapeutics Net Margin % Historical Data

The historical data trend for Neos Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics Net Margin % Chart

Neos Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Margin %
Get a 7-Day Free Trial -811.74 -824.79 -242.41 -103.37 -26.14

Neos Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.69 -20.72 -54.85 -41.94 -39.18

Competitive Comparison of Neos Therapeutics's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Neos Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neos Therapeutics's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neos Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Neos Therapeutics's Net Margin % falls into.



Neos Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Neos Therapeutics's Net Margin for the fiscal year that ended in Dec. 2019 is calculated as

Net Margin=Net Income (A: Dec. 2019 )/Revenue (A: Dec. 2019 )
=-16.902/64.649
=-26.14 %

Neos Therapeutics's Net Margin for the quarter that ended in Sep. 2020 is calculated as

Net Margin=Net Income (Q: Sep. 2020 )/Revenue (Q: Sep. 2020 )
=-4.911/12.535
=-39.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neos Therapeutics  (NAS:NEOS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Neos Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Neos Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neos Therapeutics (Neos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2940 N. Highway 360, Grand Prairie, TX, USA, 75050
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.
Executives
Alan L Heller director BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille director
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin director, officer: Chief Executive Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli officer: SVP & General Counsel 700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell officer: Chief Commercial Officer C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg officer: Chief Executive Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking officer: VP, Regulatory Affairs C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens officer: Chief Tech/Operations Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355

Neos Therapeutics (Neos Therapeutics) Headlines